Our latest research result is published in J. Med. Chem.
Great News! Immunwork’s Latest Publication Offers a Promising Clinical Solution for Diabetes, Obesity, and NASH Disease! The study, titled “2FA-Platform […]
Scientific Publication
News
Immunwork 2025 Investor Meeting – Results Presentation
Dr. Tse-Wen Chang, founder and chairman of Immunwork and T-E Meds, shared the latest developments of both companies on 15th
News
T-E Meds and Orient EuroPharma Forge Licensing Agreement for TE-1146
We are thrilled to announce that T-E Meds has licensed its novel Antibody-Drug Conjugate, TE-1146, to Orient EuroPharma. According to
News
Immunwork won the 21st National Innovation Award – Enterprise Innovation Award
Immunwork with its “Application of an Innovative Fatty Acid Bundle Platform in the Development of Ultra-Long-Acting Drugs” project, has been
Meeing
Join our presentation at the World ADC San Diego 2024
Join Dr. Art Hsing-Mao Chu, CEO of T-E Meds, at World ADC San Diego 2024 on Nov 4th to hear
Meeing
We will be participating in the 8th Taiwan Healthcare+ Expo Taiwan. Welcome to visit us
The annual Taiwan Healthcare+ Expo will be held from December 5 to 8, 2024, at Hall 1 of the Nangang
Meeing
Join our presentation at the ACCESS CHINA Partnering Forum
Dr. Kun-Po Li, the director of business development of Immunwork, will be presenting at the ACCESS CHINA Partnering Forum –
R&D Progress
Two ultra-long acting drugs receive promising news! Phase 1 clinical trials are expected to be completed next year!
Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian
Meeing
Join our presentation at the BIO Asia-Taiwan 2024 Conference
We are proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, was invited to present at the
Meeing
Join our presentation at the World ADC Asia 2024 Conference
Dr. Tse Wen Chang, Chairman and CEO of Immunwork, and Dr. Art Hsing-Mao Chu, CEO of T-E Meds, have been